Delving into the Latest Updates on Dexamethasone with Synapse

Overview

Basic Info

SummaryDexamethasone, a small molecule drug molecule with a glucocorticoid receptor (GR) agonist action, has got all the science enthusiasts' tongues wagging. The GR, which is widely distributed across various cell types, is responsible for myriad physiological responses, including immune and inflammatory responses. This small molecule drug, Dexamethasone, binds to the GR, which sends shockwaves of change through gene expression and protein synthesis, consequently giving inflammation and immune system activity a taste of their own medicine.When it comes to treating various conditions, Dexamethasone takes the crown. This potent drug has proved its mettle in treating an impressive range of conditions, including but not limited to actinic cheilitis, light chain (AL) amyloidosis, ocular inflammation, macular edema, and anaphylaxis. Back in the day, on October 30, 1958, the FDA gave the nod to Dexamethasone. It was a time when Merck & Co., Inc., a pharmaceutical company that hailed from the United States, hit the bull's eye with this innovative drug that promised a bright future.

Drug Type

Small molecule drug

Synonyms

Decadron Phosphate, Dexamethasone Intravitreal Implant, DEXTENZA

+ [47]

Target

GR

Mechanism

GR agonists(Glucocorticoid receptor agonists)

Therapeutic Areas

NeoplasmsImmune System DiseasesInfectious Diseases+ [13]

Active Indication

Immunoglobulin Light-Chain AmyloidosisOcular inflammationOphthalmologic surgical procedures+ [69]

Inactive Indication

Acute otitis externaAdvanced Head and Neck Squamous Cell CarcinomaAge Related Macular Degeneration+ [46]

Originator Organization

Merck & Co., Inc.

Active Organization

Janssen Research & Development LLC

Celgene Corp.AbbVie Deutschland GmbH & Co. KG

+ [32]

Inactive Organization

Novartis Pharmaceuticals Corp.

Tesaro, Inc.Allergan Ltd. (Ireland)

+ [22]

Drug Highest PhaseApproved

First Approval Date

US (30 Oct 1958),

AnaphylaxisEndocrine System DiseasesEye Diseases+ [7]

RegulationPriority Review (CN), Orphan Drug (US)

Login to view timeline

Structure

Molecular FormulaC22H29FO5

InChIKeyUREBDLICKHMUKA-CXSFZGCWSA-N

CAS Registry50-02-2

The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2Ds) of JNJ-75276617 in combination with a conventional chemotherapy backbone in pediatric and young adult participants with relapsed/refractory acute leukemia harboring histone-lysine N-methyltransferase 2A1 ([KMT2A1], nucleophosmin 1 gene (NPM1), or nucleoporin alterations in Part 1 (Dose Escalation) and to further evaluate safety at the RP2D(s) of JNJ-75276617 in combination with chemotherapy in pediatric and young adult participants with relapsed/refractory acute leukemia harboring KMT2A1, NPM1, or nucleoporin alterations and safety at the RP2D(s) of JNJ-75276617 as monotherapy in a select low burden of disease cohort in Part 2 (Dose Expansion).

Start Date26 Dec 2025

Sponsor / Collaborator

Janssen Research & Development LLC

CTRI/2024/10/074759 / Not yet recruitingNot ApplicableIIT

Effect of oral versus intravenous dexamethasone on duration of analgesia after osseous upper limb surgery under supraclavicular brachial plexus block - NIL

Start Date15 Sep 2025

Sponsor / Collaborator

Maulana Azad Medical College

NCT06616584 / Not yet recruitingPhase 2/3IIT

A Randomized Phase II/III Study of Docetaxel and Ramucirumab With or Without Cemiplimab for Participants Previously Treated With Platinum-Based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)

This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alone in treating patients with non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Cemiplimab is a monoclonal antibody that stimulates the immune system by blocking the PD-1 pathway. Tumors use the PD-1 pathway to escape attacks from the immune system. By blocking the PD-1 pathway, cemiplimab may help the immune system recognize and attack tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Adding cemiplimab to usual treatment, docetaxel and ramucirumab, may kill more tumor cells compared to docetaxel and ramucirumab alone in treating patients with stage IV or recurrent non-small cell lung cancer.

Start Date11 Jul 2025

Sponsor / Collaborator

SWOG

[+2]

100 Clinical Results associated with Dexamethasone

Login to view more data

100 Translational Medicine associated with Dexamethasone

Login to view more data

100 Patents (Medical) associated with Dexamethasone

Login to view more data

61,204

Literatures (Medical) associated with Dexamethasone

01 Sep 2025·Neural Regeneration Research

High-dose dexamethasone regulates microglial polarization via the GR/JAK1/STAT3 signaling pathway after traumatic brain injury

Article

Author: Lu, Shenghua ; Niu, Fei ; Wu, Hongbin ; Yang, Mengshi ; Li, Hao ; Liu, Baiyun ; Zhang, Bin ; Xu, Xiaojian ; Zhuang, Yuan ; Deng, Yu ; Dong, Xinlong ; Bai, Miao ; Ge, Qianqian

JOURNAL/nrgr/04.03/01300535-202509000-00023/figure1/v/2024-11-05T132919Z/r/image-tiff Although microglial polarization and neuroinflammation are crucial cellular responses after traumatic brain injury, the fundamental regulatory and functional mechanisms remain insufficiently understood. As potent anti-inflammatory agents, the use of glucocorticoids in traumatic brain injury is still controversial, and their regulatory effects on microglial polarization are not yet known. In the present study, we sought to determine whether exacerbation of traumatic brain injury caused by high-dose dexamethasone is related to its regulatory effects on microglial polarization and its mechanisms of action. In vitro cultured BV2 cells and primary microglia and a controlled cortical impact mouse model were used to investigate the effects of dexamethasone on microglial polarization. Lipopolysaccharide, dexamethasone, RU486 (a glucocorticoid receptor antagonist), and ruxolitinib (a Janus kinase 1 antagonist) were administered. RNA-sequencing data obtained from a C57BL/6 mouse model of traumatic brain injury were used to identify potential targets of dexamethasone. The Morris water maze, quantitative reverse transcription-polymerase chain reaction, western blotting, immunofluorescence and confocal microscopy analysis, and TUNEL, Nissl, and Golgi staining were performed to investigate our hypothesis. High-throughput sequencing results showed that arginase 1, a marker of M2 microglia, was significantly downregulated in the dexamethasone group compared with the traumatic brain injury group at 3 days post–traumatic brain injury. Thus dexamethasone inhibited M1 and M2 microglia, with a more pronounced inhibitory effect on M2 microglia in vitro and in vivo. Glucocorticoid receptor plays an indispensable role in microglial polarization after dexamethasone treatment following traumatic brain injury. Additionally, glucocorticoid receptor activation increased the number of apoptotic cells and neuronal death, and also decreased the density of dendritic spines. A possible downstream receptor signaling mechanism is the GR/JAK1/STAT3 pathway. Overactivation of glucocorticoid receptor by high-dose dexamethasone reduced the expression of M2 microglia, which plays an anti-inflammatory role. In contrast, inhibiting the activation of glucocorticoid receptor reduced the number of apoptotic glia and neurons and decreased the loss of dendritic spines after traumatic brain injury. Dexamethasone may exert its neurotoxic effects by inhibiting M2 microglia through the GR/JAK1/STAT3 signaling pathway.

01 Mar 2025·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

A Green analytical method for simultaneous determination of dexamethasone sodium phosphate and prednisolone acetate in veterinary formulations using UV spectroscopy and dimension reduction algorithms

Article

Author: Al-Ghamdi, Youssef O ; Ibrahim, Marwan A. ; Al-Ghamdi, Youssef O. ; Algohary, Ayman M. ; Ibrahim, Ahmed M ; Algohary, Ayman M ; Ibrahim, Marwan A ; Ibrahim, Ahmed M.

Precise determination of veterinary pharmaceutical concentrations represents a critical foundation for delivering safe and efficacious animal healthcare interventions. Two synthetic glucocorticoids - dexamethasone sodium phosphate (DXM) and prednisolone acetate (PRD) - are extensively employed in veterinary medicine due to their potent anti-inflammatory capabilities. Our research presents a novel, cost-effective, and environmentally sustainable analytical methodology that enables simultaneous quantification of DXM and PRD within binary veterinary formulations. The method synergistically combines UV spectroscopy with dimension reduction algorithms (DRAs), representing a significant advancement in pharmaceutical analysis. A comprehensive evaluation of seventeen DRAs was conducted using four distinct performance metrics: mean squared error (MSE), mean absolute error (MAE), median absolute error (MedAE), and coefficient of determination (R²). Among the assessed algorithms, mini-batch sparse principal component analysis demonstrated superior predictive accuracy for this specific analytical challenge. The developed method was validated using the accuracy profile approach, yielding results that confirm its satisfactory accuracy. An ecological impact assessment was conducted using five greenness evaluation tools: the Green Solvent Selection Tool (GSST), National Environmental Methods Index (NEMI), Green Certificate modified Eco-Scale, carbon footprint analysis, and the Modified GAPI (MoGAPI). In addition, whiteness was evaluated with Red-Green-Blue 12 (RGB 12) algorithms. The proposed method showed elevated GSST scores and a greener profile according to NEMI. The calculated carbon footprint was 0.0006 kg CO₂ equivalent per sample, with a Green Certificate modified Eco-Scale score of 84, a MoGAPI score of 81, and a whiteness assessment of 90.1 by the RGB12 algorithm. Statistical comparison between the proposed spectrophotometric method and a previously reported HPLC method for pharmaceutical dosage form analysis revealed no statistically significant differences at the 95 % confidence level. This study underscores the innovative combination of UV spectroscopy with dimension reduction algorithms, presenting substantial improvements over traditional UV techniques for drug analysis. This method enhances both the efficiency and accuracy of active ingredient determination in pharmaceutical dosage forms while also supporting environmental sustainability.

01 Feb 2025·COLLOIDS AND SURFACES B-BIOINTERFACES

Dexamethasone-loaded chitosan-decorated PLGA nanoparticles: A step forward in attenuating the COVID-19 cytokine storm?

Article

Author: Rocha, Helvécio Vinícius Antunes ; Tavares, Guilherme Diniz ; Sarcinelli, Michelle Alvares ; Pittella, Frederico ; Abdu, João Octavio Carneiro ; Machado Resende Guedes, Maria Clara ; Fabri, Rodrigo Luiz ; Costa, Mirsiane Pascoal ; Vilela, Fernanda Maria Pinto ; Macedo, Gilson Costa

This study aims to develop and characterize poly (lactic-co-glycolic acid) (PLGA) nanoparticles decorated with chitosan (CS) for the encapsulation of dexamethasone (DEX) (NP-DEX-CS), targeting improved efficacy in the treatment of severe acute respiratory syndrome (SARS) associated with COVID-19. The nanoparticles were systematically characterized for size, zeta potential (ZP), morphology, encapsulation efficiency, and in vitro drug release. Incorporation of CS resulted in significant modifications in the nanoparticles' physical properties, notably an increase in size (from 207.3 ± 6.7 nm to 264.4 ± 4.4 nm) and a shift in ZP to positive values (from -11.8 ±1.4 mV to +30.0 ± 1,6 mV). The NP-DEX-CS formulation achieved a high encapsulation efficiency (∼79 %) and a drug loading capacity of 6.53 ± 0.02 %.In addition, the in vitro release rate of DEX from NP-DEX-CS was lower compared to undecorated nanoparticles, with a reduction from approximately 64-37 % within 24 h. Microscopy analyses revealed a smoother surface on the CS-decorated nanoparticles. FTIR and XRD analyses confirmed successful chitosan coating and DEX encapsulation. The CS coating enhanced the tolerability of J774.A1 cells to the nanoparticles, particularly evident at the highest concentration (400ug/mL), resulting in a cell viability ≥70 %. Importantly, the NP-DEX-CS significantly reduced levels of nitric oxide and inflammatory cytokines (IL-1, IL-6, IL-12, and TNF-α). These findings suggest that CS-decorated PLGA nanoparticles hold promise as an effective dexamethasone delivery system for treating SARS related to COVID-19.

1,146

News (Medical) associated with Dexamethasone

27 Nov 2024

·www.businesswire.com

AbbVie Digital Transformation Strategy Report 2024 - Accelerators, Incubators and Other Innovation Programs - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "Enterprise Tech Ecosystem Series: AbbVie Inc. - 2024" company profile has been added to ResearchAndMarkets.com's offering. The report provides insights into AbbVie's tech activities, including its digital transformation strategies, its innovation programs, and its technology initiatives. The report provides information and insights into AbbVie's tech activities, including: Insights of its digital transformation strategies and innovation programs. Overview of technology initiatives covering partnerships and product launches. Insights on each technology initiative including technology theme, objective, and benefits. Details of estimated ICT budgets and major ICT contracts. AbbVie Inc. (AbbVie) is a multi-national, diversified research-based biopharmaceutical company engaged in developing, manufacturing, marketing, and selling medicines for serious and complex diseases. The company's product portfolio includes immunology products, oncology products, aesthetics products, neuroscience products, and eye care products. AbbVie's immunology product portfolio includes Humira, Skyrizi, and Rinvoq. Its oncology product portfolio includes Imbruvica, Venclexta, Epkinly, and Elahere. Its aesthetics product portfolio includes Botox Cosmetic, the Juvederm Collection of Fillers, Alloderm regenerative dermal tissue, and Latisse eyelash solution, among others. Its neuroscience product portfolio includes Botox Therapeutic, Vraylar, Duopa, Ubrelvy, and Qulipta, and its eye care product portfolio includes Ozurdex, Lumigan, Alphagan, and Restasis. The company also manufactures medicines for treating hepatitis C virus infection, metabolic and hormonal diseases, and endocrinology diseases. AbbVie sells its products directly to distributors, wholesalers, healthcare facilities, government agencies, independent retailers, and specialty pharmacies across the world. Reasons to Buy Gain insights into AbbVie's tech operations. Gain insights into its tech strategies and innovation initiatives. Gain insights into its technology themes under focus. Gain insights into various product launches and partnerships. Key Topics Covered: Overview Digital Transformation Strategy Accelerators, Incubators, and Other Innovation Programs Technology Focus Technology Initiatives Partnerships Network Map ICT Budget and Contracts Key Executives A selection of companies mentioned in this report includes: Reltio ConcertAI Caris Life Sciences BigHat Biosciences Cerebras Systems Accenture Pegasystems NowVertical Chronicled MC10 For more information about this company profile visit https://www.researchandmarkets.com/r/2mdpyj About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

26 Nov 2024

·www.globenewswire.com

Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences

BEDFORD, Mass. , Nov. 26, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced participation in several investor and scientific conferences being held in December. Piper Sandler 36th Annual Healthcare ConferenceFireside Chat Date: Tuesday, December 3rd, 2024 Fireside Chat Time: 1:30 PM ET Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEOLocation: New York City, NY The live fireside chat can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. FLORetina ICOOR 2024 Florence, Italy 48-week Results from the HELIOS Phase I Trial Evaluating Intravitreal OTX-TKI for Non-proliferative Diabetic RetinopathySession: Highlighted New Drugs DMEPresentation Date/Time: Thursday, December 5, 2024, 1:33 – 1:36PM CETPresenter: Dilsher S. Dhoot, MD OTX-TKI – The Evolution of Optimized AXPAXLI (AUS >> US >> SOL-1)Session: Retina Futura 1: Wet Age-Related Macular Degeneration (wAMD): Emerging Therapies and Clinical UpdatesPresentation Date/Time Friday, December 6, 2024, 11:29 – 11:33AM CETPresenter: Diana V. Do, MD HELIOS: Phase 1 SAFETY Study of AXPAXLI in NPDRSession: Retina Futura 2: Diabetic Retinal Diseases and Retinal DetachmentPresentation Date/Time: Friday, December 6, 2024, 2:12 – 2:16PM CETPresenter: Dilsher S. Dhoot, MD TKIs in the Future of Retinal Disease ManagementSession: Afternoon SymposiumSession Date/Time: Saturday, December 7, 2024, 3:30 – 4:30 PM CET About Ocular Therapeutix, Inc.Ocular Therapeutix, Inc. is a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions. AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI), Ocular’s product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD). Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and in its product candidate PAXTRAVA™ (travoprost intracameral implant or OTX-TIC), which is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Follow the Company on its website, LinkedIn, or X. The Ocular Therapeutix logo and DEXTENZA® are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc. Investors & MediaOcular Therapeutix, Inc.Bill SlatteryVice President, Investor Relationsbslattery@ocutx.com

Phase 1Phase 3Phase 2Drug Approval

25 Nov 2024

·www.businesswire.com

SpineThera Celebrates Milestone Achievement with 7th Patent Issued by the US Patent and Trademark Office

PLYMOUTH, Minn.--( BUSINESS WIRE )--SpineThera, Inc., a privately held, clinical-stage pharmaceutical company dedicated to developing medicines based on its micro-suspension platform technology, today announced The United States Patent and Trademark Office (USPTO) has issued Patent No.12,144,819. The new patent covers key aspects of SpineThera’s proprietary micro-suspension long-acting injectable technology. This innovation leverages a unique platform that allows for targeted, extended release of therapeutic agents, offering sustained effect with fewer side effects than existing treatments. By also reducing the need for frequent dosing, SpineThera’s platform is uniquely positioned to improve patient outcomes and address the urgent need for better treatment options. "Securing our seventh patent is a testament to SpineThera’s ongoing commitment to innovative research and the development of breakthrough therapies that help patients,” said Jeff Missling, CEO of SpineThera. SpineThera’s latest patent enhances the protection of its core technology and supports its flagship product, SX-600, a novel formulation of extended-release dexamethasone microspheres for transforaminal epidural injection (TF-EI) for the management of sciatica pain, currently in Ph II clinical development for patients suffering from sciatica. The issuance of this seventh patent underscores SpineThera’s strategic focus on building a robust intellectual property portfolio to protect its current and future innovations. The company continues to explore additional indications and formulations that could further expand its market reach and improve quality of life for millions of patients worldwide. For more information about SpineThera, Inc. and its pioneering work in sustained-release injectable therapies, visit www.spinethera.com About SpineThera, Inc. SpineThera is a clinical stage pharmaceutical company working to improve the lives of patients by creating injectable drugs utilizing its patented micro-suspension platform technology. SpineThera’s micro-suspension provides months long sustained-release of the active pharmaceutical ingredient with superior injectability at ultra-high concentrations. Our goal is to develop proprietary drugs that offer patients and physicians new treatment options that reduce risk, improve outcomes, and manage overall treatment costs in markets with few or no approved drugs. SpineThera's flagship investigational drug product, SX600, is a groundbreaking dexamethasone acetate micro-suspension injection which has been meticulously engineered as a targeted, extended-release corticosteroid with the potential to demonstrate a substantially improved benefit-risk profile compared to current epidural steroid injections for radicular leg pain. SpineThera is based in Medical Alley, Minnesota, the global epicenter of health innovation and care.

100 Deals associated with Dexamethasone

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00292	Dexamethasone	D07AB19 H02AB02 D10AA03	DB01234

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Immunoglobulin Light-Chain Amyloidosis	JP	Nichi-Iko Pharmaceutical Co., Ltd.	25 Aug 2021
Ocular inflammation	US	Ocular Therapeutix, Inc.	30 Nov 2018
Ophthalmologic surgical procedures	US	Ocular Therapeutix, Inc.	30 Nov 2018
Post procedural inflammation	US	EyePoint Pharmaceuticals, Inc.	09 Feb 2018
Diabetic macular oedema	EU	AbbVie Deutschland GmbH & Co. KG	26 Jul 2010
Diabetic macular oedema	IS	AbbVie Deutschland GmbH & Co. KG	26 Jul 2010
Diabetic macular oedema	LI	AbbVie Deutschland GmbH & Co. KG	26 Jul 2010
Diabetic macular oedema	NO	AbbVie Deutschland GmbH & Co. KG	26 Jul 2010
Retinal vein occlusion-related macular edema	EU	AbbVie Deutschland GmbH & Co. KG	26 Jul 2010
Retinal vein occlusion-related macular edema	IS	AbbVie Deutschland GmbH & Co. KG	26 Jul 2010
Retinal vein occlusion-related macular edema	LI	AbbVie Deutschland GmbH & Co. KG	26 Jul 2010
Retinal vein occlusion-related macular edema	NO	AbbVie Deutschland GmbH & Co. KG	26 Jul 2010
Uveitis, Posterior	EU	AbbVie Deutschland GmbH & Co. KG	26 Jul 2010
Uveitis, Posterior	IS	AbbVie Deutschland GmbH & Co. KG	26 Jul 2010
Uveitis, Posterior	LI	AbbVie Deutschland GmbH & Co. KG	26 Jul 2010
Uveitis, Posterior	NO	AbbVie Deutschland GmbH & Co. KG	26 Jul 2010
Multiple Myeloma	JP	Bristol Myers Squibb Co.	18 Jun 2010
Retinal Vein Occlusion	US	AbbVie, Inc.	17 Jun 2009
Nausea and vomiting	JP	Nichi-Iko Pharmaceutical Co., Ltd.	15 Sep 2005
Blepharitis	JP	Santen Pharmaceutical Co., Ltd.	03 Feb 1970

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pain, Postoperative	NDA/BLA	SG	AffaMed Therapeutics Co., Ltd.	19 Feb 2024
Endophthalmitis	Phase 3	US	Oculis SA	18 Dec 2023
Uveitis	Phase 3	CN	Ocumension Therapeutics	22 Aug 2022
Pain	Phase 3	US	Oculis SA	01 Jun 2022
Retinal Neoplasms	Phase 3	US	AbbVie, Inc.	12 Oct 2021
Plasmacytoma	Phase 3	US	Millennium Pharmaceuticals, Inc.	01 Dec 2015
Plasmacytoma	Phase 3	US	Biologics, Inc.	01 Dec 2015
Meniere Disease	Phase 3	US	Otonomy, Inc.	27 Oct 2015
Eye Pain	Phase 3	-	Ocular Therapeutix, Inc.	01 Apr 2014
Cataract	Phase 3	US	Icon Bioscience, Inc.	01 Jan 2014

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04246047 (DREAMM-7, ASH2024) Manual	Phase 3	Multiple Myeloma	494	Belantamab mafodotin, bortezomib, and dexamethasone (BVd)	ujpldmidoi(fgoqdkemqd) = nvmcfcesgi nsckayvnrk (dncvjdvoby, 28.4 - NR) Met View more	Positive	09 Dec 2024
				Daratumumab, bortezomib, and dexamethasone (DVd)	ujpldmidoi(fgoqdkemqd) = rxmvgdrboz nsckayvnrk (dncvjdvoby, 11.1 - 17.5) Met View more
ASH2024 Manual	Not Applicable	Multiple Myeloma First line	193	Ixazomib,LenalidomideeDexamethasonehasone (IRd)	(zbtxfaxjpc) = wykkazwemi budbuhochg (ufxmdqbbrl, 11.2) View more	Positive	09 Dec 2024
				Bortezomib,LenalidomideeDexamethasonehasone (VRd)	(zbtxfaxjpc) = tohctmuvfy budbuhochg (ufxmdqbbrl, 3.9) View more
NCT05996406 (ASH2024) Manual	Phase 2	Immunoglobulin Light-Chain Amyloidosis First line t(11;14)	29	Venetoclax + Dexamethasone	ulsvnhqiwe(xopitrtaed) = whinynsqzm fpkanmkqcy (vvctdkmweu ) View more	Positive	09 Dec 2024
ASH2024	Not Applicable	Purpura, Thrombocytopenic, Idiopathic	-	Methylprednisolone	oyguzndsox(kwtfqitkml) = Adverse events occurred in equal proportion in both the arms (methylprednisolone 28.6% (18/63), and dexamethasone 31.2% (20/64). As there were no grade three or more adverse events, they were easily managed without discontinuing the treatment. The commonest adverse event was weight gain seen in 16.5% (21/127) of the patients wsilaktpmy (gxcuwigjse )	-	09 Dec 2024
				Dexamethasone
REST (ASH2024)	Phase 2	Multiple Myeloma First line	51	Isatuximab-Bortezomib-Lenalidomide-Dexamethasone	wttrimwyad(szsnwgkxcc) = dwzczeudjx noebgxhtwx (fknumrundv, 82 - 99) View more	Positive	09 Dec 2024
NCT04756726 (CFT7455-1101, ASH2024)	Phase 1/2	Plasma cell myeloma refractory lenalidomide \| pomalidomide \| proteasome inhibitor ... View more	32	Cemsidomide	ywwavwxvie(urutongdsj) = 3 pts had an AE resulting in treatment discontinuation qxuddzsiso (zjcrpcvlny ) View more	Positive	08 Dec 2024
NCT02332850 (ASH2024) Manual	Phase 2	Multiple Myeloma	50	IsatuximabCarfilzomibDexamethasone	vzrxybudqs(rljyzpmwnb) = lnftgtvvmc chdsxppkvj (ywybvmxltu ) View more	Positive	07 Dec 2024
ASH2024	Not Applicable	Plasma cell myeloma refractory	-	Dexamethasone	jbbsjnohnd(ryizmzbjvp) = wumxvrwmqe eyjhoizcbi (naxtctooep ) View more	-	07 Dec 2024
				Tocilizumab	jbbsjnohnd(ryizmzbjvp) = bjleacoscw eyjhoizcbi (naxtctooep ) View more
ChiCTR1900020657 (1187Sirolimus, ASH2024)	Phase 3	Purpura, Thrombocytopenic, Idiopathic First line	-	HD-DXM plus sirolimus	umfgixgwbh(ruoccukepp) = gmowvrsxhx mgqnlfsyid (kwpzndpjhn ) View more	Positive	07 Dec 2024
				HD-DXM monotherapy	umfgixgwbh(ruoccukepp) = huehiniroc mgqnlfsyid (kwpzndpjhn ) View more
ChiCTR2200055486 (NEWS) Manual	Early Phase 1	Multiple Myeloma	19	塞利尼索+硼替佐米+沙利度胺+地塞米松	kdpiououwm(qhyhyirdmn) = avddkvuktv vojazabhkh (smzhevidys ) View more	Positive	11 Nov 2024